reports
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend...
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Acer Therapeutics Shareholders Vote "FOR" the Proposed Merger and Related Proposals Acer Shareholders – Please Vote Today! NEWTON, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: ), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today announced that Institutional Shareholder Services Inc. (ISS) and Glass, Lewis & Co. LLC (Glass Lewis) recommended that Acer shareholders vote "FO...
Acer Therapeutics Reacquires Worldwide Development, Commercialization ...
Acer Therapeutics Reacquires Worldwide Development, Commercialization and Economic Rights to OLPRUVA™ from Relief Therapeutics, Excluding the Geographical Europe NEWTON, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: ), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today announced it has entered into definitive agreements to reacquire worldwide development, commercialization and economic rights to OLPRUVA™ (sodium phenylbutyrate) from Relief Thera...
Acer Therapeutics Reports Second Quarter 2023 Financial Results and Pr...
Acer Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update OLPRUVA™ (sodium phenylbutyrate) kits now available in all dosage strengths and ready to ship to patients NEWTON, Mass., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update. “The ...
Acer Therapeutics Receives $1 Million Capital Infusion from Chief Exec...
Acer Therapeutics Receives $1 Million Capital Infusion from Chief Executive Officer and Founder Promissory note extends cash runway into early Q3 2023 OLPRUVA™ expected to be available by prescription in the U.S. beginning July 5th NEWTON, Mass., June 26, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: ), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today announced it has received $1,000,000 in funding in exchange for the issuance of an unsecured, subordinated ...
Acer Therapeutics Reports Q1 2023 Financial Results and Provides Corpo...
Acer Therapeutics Reports Q1 2023 Financial Results and Provides Corporate Update U.S. OLPRUVA™ launch progressing ahead of schedule with drug-in-channel now anticipated in mid-June 2023 NEWTON, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the first quarter ended March 31, 2023 and provided a corporate update. “The first quarter of 2...
Acer Therapeutics Announces OLPRUVA™ Commercial Launch Progressing Ahe...
Acer Therapeutics Announces OLPRUVA™ Commercial Launch Progressing Ahead of Schedule Availability: OLPRUVA™ drug in channel now anticipated in mid-June 2023 Awareness: 70% of metabolic treatment providers surveyed by Acer at SIMD Annual Meeting indicated an interest in treating at least one of their patients with OLPRUVA™ in 2023 Reimbursement: Acer engaged in discussions with payers representing a substantial majority of covered lives NEWTON, Mass., May 01, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: ), a pharmaceutical company focused on the acquisition, development and commercialization of ...
Acer Therapeutics Reports Q4 and Full Year 2022 Financial Results and ...
Acer Therapeutics Reports Q4 and Full Year 2022 Financial Results and Provides Corporate Update NEWTON, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today reported financial results for Q4 and full year ended December 31, 2022, and provided an update on the Company’s recent corporate developments. “2022 marked Acer’s first U.S. Food and Drug Administration (FDA) product...
Acer Therapeutics Announces Data Presented at Society for Inherited Me...
Acer Therapeutics Announces Data Presented at Society for Inherited Metabolic Disorders Annual Meeting Identifying Preferred Urea Cycle Disorder Treatment Attributes Results from survey of Urea Cycle Disorders (UCD) healthcare providers show taste and odor were the most important attributes when considering treatment options and treatment adherence NEWTON, Mass., March 22, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: ), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical ...
Acer Therapeutics Announces $2.675 Million Registered Direct Offering ...
Acer Therapeutics Announces $2.675 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules NEWTON, Mass., March 22, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: ), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today announced that it has entered into a definitive agreement for the purchase and sale of 2,920,306 shares of the Company’s common stock (or common stock equivalents) at a purchase price of $0.916 per share of common stock (or common...
Acer Therapeutics Announces Topline Results from ACER-801 (Osanetant) ...
Acer Therapeutics Announces Topline Results from ACER-801 (Osanetant) Phase 2a Trial ACER-801 safe and well-tolerated but did not achieve statistically significant decrease in frequency or severity of hot flashes in postmenopausal women NEWTON, Mass., March 17, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: ), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today announced that topline results from its Phase 2a proof of concept clinical trial to evaluate ACER-801...
Acer Therapeutics Announces Presentation of HCP Urea Cycle Disorder Tr...
Acer Therapeutics Announces Presentation of HCP Urea Cycle Disorder Treatment Preference Data at the Society for Inherited Metabolic Disorders Annual Meeting and Provides OLPRUVA™ Program Update Results to be presented from a survey designed to quantify treatment preferences of healthcare providers for Urea Cycle Disorders (UCDs) OLPRUVA™ preliminary launch activities progressing; building out commercial and medical affairs teams to support U.S. launch in Q2 2023, with drug availability anticipated by early July 2023 NEWTON, Mass., March 15, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: ), a pharm...
Acer Therapeutics Announces Full Enrollment of Phase 2a Trial of ACER-...
Acer Therapeutics Announces Full Enrollment of Phase 2a Trial of ACER-801 (Osanetant) for Treatment of Moderate to Severe Vasomotor Symptoms Associated with Menopause Topline trial results expected mid-March 2023 NEWTON, Mass., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today announced full enrollment of its Phase 2a proof of concept trial of ACER-801 (osanetant), a novel, n...
Acer Therapeutics Highlights Key 2022 Achievements and Pipeline Advanc...
Acer Therapeutics Highlights Key 2022 Achievements and Pipeline Advancements, and Provides Anticipated 2023 Milestones NEWTON, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- NEWTON, MA – January 09, 2023 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today announced a corporate update and provided anticipated key development milestones for 2023. “The U.S. approval of OLPRUVA™ (sodium phenylbutyrate) for oral suspen...
Acer Therapeutics Announces Initiation of Two Investigator-Sponsored T...
Acer Therapeutics Announces Initiation of Two Investigator-Sponsored Trials of ACER-801 (Osanetant) in Men with Adenocarcinoma of the Prostate POSH-MAP and PORT-MAP investigator-sponsored trials to evaluate ability of ACER-801 (osanetant) to reduce hot flashes and as neoadjuvant therapy in men with prostate cancer NEWTON, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, toda...
Acer Therapeutics Compliant with All Nasdaq Listing Criteria
Acer Therapeutics Compliant with All Nasdaq Listing Criteria NEWTON, Mass., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that The Nasdaq Stock Market LLC has formally notified Acer that the company has regained compliance with the $35 million market value of listed securities requirement, and otherwise satisfies all other criteria necessary, for continued listing ...
Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval o...
Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of OLPRUVA™ for Patients with Urea Cycle Disorders New FDA-approved formulation for patients living with urea cycle disorders $42.5 million of non-dilutive debt funding available to Acer that, if drawn, would extend cash runway into H2 2023 NEWTON, Mass. and GENEVA, Dec. 27, 2022 (GLOBE NEWSWIRE) -- (Nasdaq: ) (“Acer”) and its collaboration partner, (SIX: , OTCQB: , ) (“Relief”), today announced that the U.S. Food and Drug Administration (FDA) has approved OLPRUVA™ (sodium phenylbutyrate) for oral suspension in the ...
- Jonathan Moreland
PLD PROLOGIS INC.
NGL NGL ENERGY PARTNERS LP
MOFG MIDWESTONE FINANCIAL GROUP
FAST FASTENAL COMPANY
ENZ ENZO BIOCHEM INC.
CLMT CALUMET SPECIALTY PRODUCTS PARTNERS L.P.
BCOV BRIGHTCOVE
EVA ENVIVA PARTNERS LP
ET ENERGY TRANSFER L.P.
PLAB PHOTRONICS INC.
UHAL AMERCO
JELD JELD-WEN HOLDING INC.
IOVA IOVANCE BIOTHERAPEUTICS INC
BCBP BCB BANCORP INC.
ACER ACER THERAPEUTICS
BRT BRT APARTMENTS
SCPH SCPHARMACEUTICALS INC
TDW TIDEWATER INC
GIM TEMPLETON GLOBAL INCOME FUND
GLG CHINA COMMERCIAL CREDIT
AMEH APOLLO MEDICAL HOLDINGS INC
HHC THE HOWARD HUGHES CORPORATION
BW BABCOCK & WILCOX ENTERPRISES
XAIR BEYOND AIR
EFT EATON VANCE FLOATING RATE INCOME TRUST
VOXX AUDIOVOX CORPORATION
GOCO GOHEALTH
RILY INC.
RKT B. RILEY FINANCIAL
FGF ROCKET COMPANIES
WRAP FG FINANCIAL GROUP INC
PNT WRAP TECHNOLOGIES INC
AATC POINT BIOPHARMA GLOBAL INC
BODY AUTOSCOPE TECHNOLOGIES CORP
EMO FOREST ROAD ACQUISITION CORP.
TMAC CLEARBRIDGE ENERGY MLP OPPORTUNITY FUND INC.
UAMY MUSIC ACQUISITION CORP
U S ANTIMONY CORP
- Jonathan Moreland
CLMT CALUMET SPECIALTY PRODUCTS PARTNERS L.P.
ACER ACER THERAPEUTICS
GIM TEMPLETON GLOBAL INCOME FUND
AMEH APOLLO MEDICAL HOLDINGS INC
EFT EATON VANCE FLOATING RATE INCOME TRUST
VOXX AUDIOVOX CORPORATION
GOCO GOHEALTH
RILY INC.
HRMY B. RILEY FINANCIAL
LUMN HARMONY BIOSCIENCES HOLDINGS
WRAP LUMEN TECHNOLOGIES INC.
EMO WRAP TECHNOLOGIES INC
CLEARBRIDGE ENERGY MLP OPPORTUNITY FUND INC.
Acer Therapeutics Announces $1.5M Private Placement
Acer Therapeutics Announces $1.5M Private Placement NEWTON, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today announced that it has entered into definitive agreements with its CEO as well as its Chairman for a private placement of its securities for gross proceeds of $1.5 million. On November 29, 2022, Acer entered into a securities purchase agreement for the sale and i...
Acer Therapeutics Reports Q3 2022 Financial Results and Provides Corpo...
Acer Therapeutics Reports Q3 2022 Financial Results and Provides Corporate Update NEWTON, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the third quarter ended September 30, 2022 and provided an update on Acer’s recent corporate developments. “I am pleased with our team’s progress in the third quarter, highlighted by the timely resubmi...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.